Rheumatoid arthritis (RA), Crohn's disease and multiple sclerosis are common diseases, which are directly related to interactions developed between a protein called the Tumour Necrosis Factor (TNF) and its receptors. Current drugs that effectively disrupt TNF-receptor associations also cause serious side effects. In this feature, we present a computational scheme that resulted in the discovery of two non-toxic compounds, which directly inhibit TNF function. Moreover, the polypharmacology of these compounds was demonstrated as they were also found to inhibit the function of RANKL, a member of the TNF protein family. Optimization of the compounds may lead to the development of new medications for inflammatory and autoimmune treatments.
Virtual screening accelerates antiinflammatory drug discovery
Drug design directed at developing small-molecule TNF inhibitors can effectively overcome most of the above impediments, although it is far from being a trivial task in pharmaceutical research. Successful drug design requires the identification of compounds with low molecular weight, something extremely challenging, especially when attempting to block interactions between large molecules such as proteins. A very potent TNF inhibitor, SPD304, directly hinders TNF trimerization by blocking the formation of the biologically active complex; however, SPD304 appeared to be significantly toxic. Despite a few additional compounds that have recently been identified as direct TNF inhibitors, little progress has been made regarding the discovery of effective and harmless biological agents against inflammation.
Computational chemistry approaches can be particularly useful in the identification of compounds that match the aforementioned requirements for anti-inflammatory action and low toxicity. This can be achieved by applying a combination of molecular mechanics theory with simple energy terms (i.e., electrostatic, van der Waals, hydrogen bond and hydrophobic interactions) to virtual atoms that represent molecular structures (compounds and protein) in order to predict the strength of association between a compound and the TNF Tumour Necrosis Factor (TNF) is a protein that is implicated in a wide range of chronic inflammatory and autoimmune disorders, such as RA, Crohn's disease, psoriasis and multiple sclerosis. These conditions are very common, as they affect 0.5 to 1% of the population worldwide. Current efforts to control these pathological functions have been focused on the interruption of TNF binding to associated protein receptors. However, existing treatments remain inadequate and generate significant side effects, thus reducing the quality of life. Moreover, these treatments mainly target the symptoms of relevant inflammatory diseases but not their causes, and do not provide a longterm cure, thus demanding further research for the development of improved therapeutics. To date, several synthetic pharmaceutical drugs have come to the market as potent TNF inhibitors (for example, infliximab, adalimumab and entanercept). Unfortunately, these drugs are effective in only 60% of patients, and in those with long-standing disease, the response can be transient with approximately half of patients becoming refractory to treatment within 2 years. There is clearly a need for an orally available, well-tolerated, inexpensive drug that could block the action of TNF associated with pathological inflammation found in rheumatoid arthritis and related conditions. Inflammation protein. The process of collecting, retrieving, storing, combining and applying information about molecular structure, physico-chemical properties, docking sites and other relevant parameters is generally called cheminformatics. In the search for new anti-TNF compounds, various cheminformatics methods can be combined with molecular dynamics (a computer application that simulates the motion and evolution of atoms and molecules) to recognize substances as candidates for effective TNF inhibition.
To aid the discovery of improved drugs that effectively inhibit TNF action, a new computer-based platform for the virtual screening of large data sets of compounds has been developed. This platform uses a combination of several computational algorithms to predict the interactions and binding of small molecules to TNF. Thus, the chemical structures of over 14,000 diverse compounds with unidentified activities were virtually screened to estimate how effectively these molecules disrupt TNF trimerization. This procedure led to the 'filtering' of nine small molecules as potential candidate inhibitors. Importantly, these predictions were further validated through biological experiments that were conducted via traditional laboratory practices. The successful application of the above-mentioned computational protocol and the subsequent experimental validation resulted in the identification of two particularly effective TNF inhibitors, namely compounds T23 and T8. Toxicity indexes for both compounds were also estimated to be very low, thus suggesting they may be administered without severe side effects. A representative image of the most potent compound (T23) in TNF is shown in Figure 1 . Experimental testing for thousands of compounds is unfeasible on a realistic timescale, and even for a much smaller number of molecules, their evaluation is a very slow and expensive procedure. The main advantage of computational approaches is that one may obtain reliable predictions in a very fast and low-cost way, thus greatly facilitating drug discovery.
Polypharmacology could enhance drug action and reduce side effects
Generally, pharmaceutical molecules interact with multiple target proteins, thus exerting secondary, often unwanted actions. Therefore, drug design procedures usually focus on the identification of substances that display major selectivity toward a particular target. However, in some cases, high binding affinity of a molecule to multiple target proteins may be desirable, considering that binding to several specific receptors may produce enhanced actions or compensate harmful effects. This approach is known as polypharmacology or multi-target drug design.
Inhibition of another protein, RANKL (Receptor activator of nuclear factor kappa-B ligand), has been shown to significantly diminish fracture incidents in postmenopausal women and a recent RANKL inhibitor has been recognized for its profound therapeutic effects against osteoporosis. RANKL belongs to the same protein family as TNF and constitutes an ideal target to evaluate the polypharmacologic potential of Inflammation T23 and T8. Initial computational considerations were subsequently confirmed through biological assessments and demonstrated the inhibitory action of the two compounds against RANKL as well. Similar to the TNF system, RANKL inhibition was not accompanied by any significant toxic effects; therefore, it was demonstrated that T23 and T8 act as dual inhibitors of TNF and RANKL. This finding denotes the advanced pharmacological actions T23 and T8 may exert, thus further strengthening their role as potent antiinflammatory agents.
Compound screening against inflammation made easy
The above computational scheme may significantly aid the development of new medications for the treatment of inflammation and autoimmune diseases, however, the successful application of such approaches is a complicated task since it requires specialized knowledge and a solid background in cheminformatics and molecular simulation techniques. To make the model predictions of drug candidates accessible to any interested user, the proposed model was built based on open source algorithms and was made publicly available online through the Enalos Cloud Platform (http://enalos.insilicotox.com/TNFPubChem/). The web service does not require special computational skills and can be easily operated by diverse groups of scientists like chemists, biologists, engineers, physicists or even non-experts involved or interested in effective TNF inhibition by new chemical substances. In this way, the complex computational algorithms are incorporated in the platform, which operates in an automated fashion by simply feeding molecular structures for further inhibition evaluation. Next, the platform quickly generates output predictions regarding the inhibitory potency of any drug candidate against TNF. The Enalos Cloud Platform is a web service that incorporates a fully validated, predictive model that can be used in small molecule anti-inflammatory drug design.
Future perspectives
Combating inflammatory and autoimmune diseases requires the ever-increasing efforts of multidisciplinary areas of science toward the development of potent and risk-free medications. In this direction, the use of computational chemistry may greatly facilitate the discovery of new compounds, which prevent specific interactions between TNF or RANKL and other proteins without inducing unwanted side effects (for instance, computationally identify and exclude from further study, pan-assay interference compounds (PAINS)). Then, newly discovered anti-inflammatory compounds, such as T23 and T8, may be used as direct Inflammation protein inhibitors or they could serve as molecular templates for further computational optimization, in search of optimal treatments against autoimmune conditions and inflammation. The development and public dissemination of a web-based platform (Enalos Cloud) for the fast and accurate virtual screening of small molecules can rapidly advance the identification of other (possibly improved) compounds as potent TNF or RANKL inhibitors. Importantly, the Enalos platform can be easily expanded to include other target proteins, thus also enabling the reliable virtual screening of compounds related to a wide range of additional diseases. ■ Further reading
